Role of DiCE in GUIDE.MRD
DiCE is a European umbrella organization of nearly 40 national patient organizations distributed in 32 European countries.
DiCE co-led the patient advisory board (consulted on their understanding of ctDNA (circulating tumor DNA) and MRD (minimal residual disease), interpreting and acting on test reports, and reviewing documents and reports).
DiCE contributes to: set-up a patient advisory board; stakeholder engagement and other measures to maximize impact, to ensure that the needs of patients and guiding principles for patient-friendly data governance are integrate; dissemination and communication to the patient community help shaping, building and reviewing materials towards patients and co-author relevant publications as per scientific journal guidelines, understand stakeholder needs and healthcare pathway expectations and align with project activities and outcomes, and multi-stakeholder dialogues on decision making in precision oncology.
Why does DICE participate in the GUIDE.MRD project?
Part of our mission is to leverage patient’s views and needs to improve QoL (quality of life) and the survival of digestive cancer patients and their prevention. GUIDE.MRD represents a unique opportunity to rethink the design and development of scientific projects and clinical trials, ensuring patients’ voices are incorporated in a co-creation process that will provide targeted solutions and more sustainable results.
DiCE Principal Investigators involved in GUIDE.MRD
